NCT05546554View on ClinicalTrials.gov

Trial of Suvorexant for Sleep in Children With Autism

PHASE2RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 9, 2023

Primary Completion Date

February 28, 2028

Study Completion Date

February 28, 2028

Conditions
AutismAutism Spectrum Disorder
Interventions
DRUG

Suvorexant

5 mg (and up to 20 mg) Suvorexant given orally

DRUG

Placebo

Matching Placebo given orally

Trial Locations (1)

94305-5719

RECRUITING

Stanford University, Stanford

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Stanford University

OTHER